araag2/HINT huggingface dataset:
Clinical trial NCT00309972 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: control arm (seq):, experimental arm (con):
SMILES: CC1=CC(O)=CC(C)=C1Cl, C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC)

               -  Patients with stage IIIB disease must not have a pleural effusion that is
                  cytologically proven to be malignant

          -  Inoperable disease

          -  Disease must be able to be encompassed within a radical radiotherapy treatment volume

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0 or 1

          -  Life expectancy > 3 months

          -  Patient considered able to tolerate platinum-based chemotherapy and radical
             radiotherapy

          -  Glomerular filtration rate ≥ 60 mL/min

          -  WBC > 3,000/mm³

          -  Absolute neutrophil count > 1,500/mm³

          -  Hemoglobin > 10.0 g/dL

               -  Patients with hemoglobin between 10 and 12 g/dL at randomization require a blood
                  transfusion to ensure hemoglobin > 12 g/dL before starting radiotherapy

          -  Platelet count > 100,000/mm³

          -  FEV_1 ≥ 1.0 L or DLCO (transfer factor) ≥ 50% of predicted

          -  Alkaline phosphatase ≤ 1.5 times upper limit of normal (ULN)

          -  Gamma-glutamyl-transferase < 1.5 times ULN

          -  Transaminases ≤ 1.5 times ULN

          -  Bilirubin ≤ 1.5 times ULN

          -  No medically unstable conditions (e.g., unstable diabetes, uncontrolled arterial
             hypertension, infection, hypercalcemia, or ischemic heart disease)

          -  Not pregnant or nursing

          -  Fertile patients must agree to use effective contraception

          -  Negative pregnancy test

          -  No other previous or current malignant disease likely to interfere with protocol
             treatment or comparisons

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy, radiotherapy, or investigational agents
Clinical trial NCT01327222 (phase 3, status: completed)
Conditions: age related macular degeneration
ICD codes: H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  age-related macular degeneration

          -  naïve subfoveal choroidal neovascularization

          -  best-corrected visual acuity less then 20/200

        Exclusion Criteria:

          -  previous treatments

          -  any other condition able to limit the visual improvement
Clinical trial NCT01297517 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, brinzolamide ophthalmic suspension, 1%, brimonidine tartrate ophthalmic solution, 0.2%
SMILES: BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Sign Informed Consent document.

          -  Diagnosis of open-angle glaucoma or ocular hypertension, with mean intraocular
             pressure within protocol-specified range at eligibility visit/s.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Females of childbearing potential if pregnant, lactating, or not using highly
             effective birth control measures.

          -  Any form of glaucoma other than open-angle glaucoma.

          -  Severe central vision loss in either eye.

          -  Chronic, recurrent, or severe inflammatory eye disease.

          -  Ocular trauma within the preceding 6 months.

          -  Ocular infection or ocular inflammation within the preceding 3 months.

          -  Clinically significant or progressive retinal disease such as retinal degeneration,
             diabetic retinopathy, or retinal detachment.

          -  Best-corrected visual acuity score worse than 55 letters using the Early Treatment
             Diabetic Retinopathy Study chart.

          -  Other ocular pathology (including severe dry eye) that may, in the opinion of the
             Investigator, preclude the administration of study product.

          -  Ocular surgery within the preceding 6 months.

          -  Ocular laser surgery within the preceding 3 months.

          -  Any abnormality preventing reliable applanation tonometry.

          -  Any other conditions, including severe illness, which could make the patient, in the
             opinion of the Investigator, unsuitable for the study.

          -  Other protocol-specified exclusion criteria may apply.
Clinical trial NCT00257075 (phase 3, status: completed)
Conditions: bipolar disorders, manic episode
ICD codes: F30.9, F30.3, F30.4, F30.10, F30.11, F30.12, F30.13
Drugs: risperidone, oral tablets
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of Bipolar I Disorder, Most Recent Episode Manic, by the
             criteria in the Diagnostic and Statistical Manual of Mental Diseases, 4th edition
             (DSM-IV)

          -  voluntarily hospitalized at study initiation for the current manic episode

          -  history of at least one documented manic or mixed episode that required treatment
             prior to study initiation

          -  total score of >=20 on the Young Mania Rating Scale (YMRS) and total score of <=20 on
             the Montgomery Asberg Depression Rating Scale (MADRS) at start of the study

        Exclusion Criteria:

          -  Patients who meet DSM-IV criteria for Schizoaffective Disorder or for rapid cycling

          -  with borderline or antisocial personality disorder

          -  history of substance dependence (excluding nicotine and caffeine) within the 3 months
             prior to study initiation

          -  with seizure disorder

          -  females who are pregnant or nursing, or those lacking adequate contraception.
Clinical trial NCT00622349 (phase 3, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: cisplatin, ifosfamide, gemcitabine, ifosfamide, gemcitabine, cisplatin, docetaxel
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], ClCCNP1(=O)OCCCN1CCCl, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of non-small cell lung cancer

          -  Advanced (unresectable or functionally inoperable) stage III or stage IV disease

          -  Availability for participating in the detailed follow-up of the protocol

          -  Presence of an evaluable or measurable lesion

          -  Informed consent

        Exclusion Criteria:

          -  Prior treatment with chemotherapy

          -  Operable patient with resectable tumour

          -  Performance status < 60 on the Karnofsky scale

          -  A history of prior malignant tumour, except non-melanoma skin cancer or in situ
             carcinoma of the cervix and cured malignant tumour (more than 5-year disease free
             interval)

          -  Polynuclear cells < 2,000/mm³

          -  Platelet cells < 100,000/mm³

          -  Serum bilirubin >1.5 mg/100 ml

          -  Serum creatinine > 1.5 mg/100 ml and/or creatinine clearance < 60 ml/min

          -  Perception hypoacousia

          -  Peripheral neuropathy

          -  Recent myocardial infarction (less than 3 months prior to date of diagnosis)

          -  Congestive cardiac failure requiring medical therapy or uncontrolled cardiac
             arrhythmia

          -  Uncontrolled infectious disease

          -  Serious medical or psychological factors which may prevent adherence to the treatment
             schedule
Clinical trial NCT00363636 (phase 3, status: terminated)
Conditions: lymphoma, non-hodgkin's
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: galiximab in combination with rituximab, rituximab in combination with placebo
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    enrollment challenges due to changes in standards of care resulted in premature termination. no
    safety or efficacy events factored into this action.
  
Eligibility criteria:

        Key Inclusion Criteria:

        Key Inclusion Criteria:

          -  Aged >= 18 years old at the time of informed consent.

          -  Histologically confirmed follicular Grade 1-3a NHL.

          -  Relapsed or progressive disease after at least 1 prior chemotherapy requiring
             treatment.

          -  Bidimensionally measurable disease with at least 1 lesion >= 2.0 cm in a single
             dimension.

          -  Acceptable hematologic, hepatic, and renal function parameters.

          -  Recovered fully from any significant toxicity associated with prior surgery, radiation
             treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell
             transplant, or investigational drugs.

        Key Exclusion Criteria:

          -  Follicular lymphoma Grade 3b.

          -  Rituximab refractory or refractory to anti-CD20 radioimmunotherapy (no response to
             prior rituximab or prior rituximab-containing regimen, or a response with a TTP of
             less than 6 months).

          -  Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study
             Day 1 (6 weeks if nitrosourea or mitomycin C).

          -  Prior lymphoma vaccine therapy within 12 months prior to Study Day 1.

          -  Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months
             prior to Study Day 1.

          -  Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1.

          -  Prior allogeneic transplant.

          -  Transfusion-dependent subjects.

          -  Another primary malignancy requiring active treatment (except hormonal therapy).

          -  Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active
             uncontrolled bacterial, viral, or fungal infections; or other conditions, which would
             compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

          -  New York Heart Association Class III or IV cardiac disease or myocardial infarction
             within 6 months prior to Study Day 1.
Clinical trial NCT00461032 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: montelukast, comparator: placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female non-smoking Participants, ages 6 to 14 years, with chronic asthma,
             history of at least one asthma exacerbation associated with a cold within the past
             year and a documented history of asthma that required treatment with any asthma
             medication within 6 months prior to Visit 1

        Exclusion Criteria:

          -  Participant cannot have any other acute or chronic pulmonary disorder, or
             hospitalization for asthma more than three times within one year prior to signing
             informed consent
Clinical trial NCT01421459 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2963016, lantus, oams
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Have Type 2 Diabetes Mellitus based on the disease diagnostic criteria World Health
             Organization (WHO) classification

          -  Have been taking at least 2 types of oral diabetes medications for at least 12 weeks
             prior to entering the study

          -  Have a Hemoglobin A1c value greater than or equal to 7.0 percent and less than or
             equal to 11.0 percent if insulin naive If previously on Lantus, then Hemoglobin A1c
             must be less than or equal to 11.0 percent

          -  Have a body mass index of less than or equal to 45 kilogram per meter squared (kg/m^2)

        Exclusion Criteria:

          -  Have significant liver, cardiac or gastrointestinal disease

          -  Have active cancer or have had cancer within the past 5 years (with the exception of
             basal cell carcinoma or carcinoma in situ)

          -  Have an excessive resistance to insulin or hypersensitivity to Lantus

          -  Have had more than one episode of severe low blood sugar (defined as needing someone
             else to help because you had very low blood sugar) within the 6 months before entering
             the study

          -  Have taken any other insulin other than Lantus within the past 30 days

          -  Taking any other diabetes medicines that are not allowed in the study or not approved
             to be taken with insulin
Clinical trial NCT01059812 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, biphasic insulin aspart 30
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female at least 18 years of age (at least 20 years for Japan)

          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

          -  Subject on basal human or analogue insulin, once daily (OD) or twice daily (BID) with
             or without metformin for at least 3 months or subject on premixed human or analogue
             insulin or self-mixed insulin regimen, containing 20-40% fast/rapid-acting component,
             OD or BID, with or without metformin, for at least 3 months

          -  HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

          -  Body mass index (BMI) maximum 35.0 kg/m^2

        Exclusion Criteria:

          -  Treatment with oral antidiabetic drugs (OADs) (except metformin) within the last 8
             weeks prior to Visit 1

          -  Treatment with thiazolidinediones (TZDs) or glucagon like peptide 1 (GLP-1) receptor
             agonists within 3 months prior to Visit 1

          -  Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
             180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements

          -  Cancer and medical history of cancer (except basal cell skin cancer or squamous cell
             skin cancer)
Clinical trial NCT01146951 (phase 3, status: completed)
Conditions: lennox-gastaut syndrome
ICD codes: G40.813, G40.814, G40.811, G40.812
Drugs: rufinamide (e2080), placebo
SMILES: NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria

          1. Participants who are diagnosed as Lennox-Gastaut syndrome with tonic/atonic seizures
             and atypical absence seizures (A history of atypical absence seizures will also be
             incorporated).

          2. Participants who had a slow spike-and-wave pattern in an electroencephalogram within 6
             months prior to the enrollment for the Observation Period.

          3. Participants who had at least a total of 90 seizures in the 28 days prior to the
             enrollment for the Observation Period.

          4. Participants who have been on 1 - 3 anti-epileptic drugs from 28 days prior to the
             enrollment for the Observation Period and have not changed the type of the
             anti-epileptic drugs.

          5. Participants who have not changed the type nor the dose or administration of the
             anti-epileptic drugs they are taking in the Observation Period.

        Exclusion criteria;

          1. Participants who had a history of generalized tonic-clonic status epilepticus within
             baseline.

          2. Participants who received drug therapy at least 4 times to be rescued from status
             epilepticus within baseline.

          3. Participants who had a history of hypoxia which needed emergency resuscitation within
             12 months prior to the Treatment Period.

          4. Participants who were on a ketogenic diet or have received adrenocorticotropic hormone
             (ACTH) therapy or Vitamin B6 therapy within 6 months prior to the Treatment Period.

          5. Participants who had a history of suicide attempt within the 1 year prior to the
             Treatment Period.

          6. Participants who had a history of or has an allergy to triazole compound.

          7. Participants who have clinically significant electrocardiogram abnormalities at
             baseline.

          8. Participants who are pregnant, who may be pregnant, who are lactating or who wish to
             be pregnant.
Clinical trial NCT00657553 (phase 3, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with multiple myeloma currently or previously enrolled on UARK 98-026 and
             currently event-free at the time of the evaluation.

          -  Performance status of 0-2 based of Southwest Oncology Group (SWOG) criteria

          -  Previously documented platelet count > 75,000/ul within a 35 days prior to enrollment

          -  Previously documented peripheral absolute neutrophil count >1,000/ul within 35 days
             prior to enrollment.

          -  Adequate renal function

          -  Signed informed consent

          -  Female subject is post-menopausal or willing to use acceptable birth control

          -  Male subjects agree to use acceptable method of contraceptive

        Exclusion Criteria:

          -  Hypersensitivity to Bortezomib, boron, or mannitol

          -  Female subject is pregnant or breastfeeding

          -  Experienced myocardial infraction within 6 months prior to enrollment

          -  Received other investigational new drugs within 14 days before enrollment

          -  Received any anti-myeloma therapy within 14 days

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study

          -  Diagnosed or treated for another malignancy within 3 years of enrollment
Clinical trial NCT00561470 (phase 3, status: completed)
Conditions: colorectal neoplasms, neoplasm metastasis
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: placebo, aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrap®), folfiri (irinotecan, 5-fluorouracil, and leucovorin), folfiri (irinotecan, 5-fluorouracil, and leucovorin)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O, FC1=CNC(=O)NC1=O, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Participants who met the following main selection criteria were included in the study.

        Inclusion Criteria:

          -  Histologically or cytologically proven adenocarcinoma of the colon or rectum

          -  Metastatic disease that is not amenable to potentially curative treatment

          -  One and only one prior line of treatment for metastatic disease. This prior line
             should be an oxaliplatin based chemotherapy (participants who relapse within 6 months
             of completion of oxaliplatin based adjuvant chemotherapy are eligible)

          -  Prior treatment with bevacizumab is permitted.

        Exclusion Criteria:

          -  Prior therapy with irinotecan

          -  Eastern Cooperative Oncology Group performance status >2

        The above information is not intended to contain all considerations relevant to
        participation in a clinical trial.
Clinical trial NCT00373789 (phase 3, status: terminated)
Conditions: urinary incontinence, detrusor overactivity, urinary urgency, urge urinary incontinence
ICD codes: N39.492, R32, R39.81, N39.498, L24.A2, R46.3, E27.0, N39.41, N39.46, N39.490, N39.491, N39.492, R32, R39.81
Drugs: botulinum toxin a, bladder detrusor muscle injection, vehicle saline as placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    higher than anticipated rate of increased post-void residual in subjects who received botulinum
    toxin a injection
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult women

          -  Detrusor overactivity incontinence confirmed by urodynamic testing

          -  Symptoms refractory to standard first- and second-line treatments

          -  6 or more urge incontinence episodes on 3-day bladder diary

          -  Normal neurological examination

        Exclusion Criteria:

          -  Urinary retention

          -  Allergy to Botox (Botulinum Toxin A)

          -  Previous bladder treatment with Botox (Botulinum Toxin A) in the past year

          -  Pregnancy or planning pregnancy within next year

          -  Neurologic disease with impaired neurotransmission
Clinical trial NCT01342016 (phase 3, status: terminated)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: tacrolimus capsule, tacrolimus placebo, leflunomide tablet, leflunomide placebo, prednisone
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F, CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Reason stopped: 
    due to safety concern of active control drug
  
Eligibility criteria:

        Inclusion Criteria:

          -  body weight 40-100kg

          -  diagnosed as systemic lupus erythematosus, (according to American College of
             Rheumatology Diagnostic Criteria,1997)

          -  diagnosed as type III/ IV of lupus nephritis by renal biopsy within 6 months

          -  24hr proteinuria ≥2g and/or active urinary sediments

        Exclusion Criteria:

          -  receiving immunosuppressant

          -  receiving routine treatment of tacrolimus and leflunomide within 1 month

          -  receiving nonsteroidal anti-inflammatory drugs (NSAIDs) within 1 months before the
             study

          -  history of allergy to tacrolimus and leflunomide

          -  anticipated maintenance dialysis persisted over 8 weeks; or already being dialyzed
             over 2 weeks before recruitment

          -  planning to receive kidney transplantation or in the near future or having a history
             of undergoing kidney transplantation

          -  serum creatinine (Scr) ≥3mg/dl or estimated glomerular filtration rate (eGFR) <
             30ml/min

          -  diabetes mellitus patients